SCI Business Summary

SCI Pharmtech (4119.TW) is a premier Taiwanese manufacturer of Active Pharmaceutical Ingredients (APIs) and drug intermediates, primarily generating revenue through the global sale of high-purity chemical compounds to generic and branded pharmaceutical firms. As of early 2026, the company’s revenue is anchored by its API segment (approximately 71%), followed by intermediates (27%) and specialty chemicals (2%), with a strategic focus on therapeutic areas such as anti-epileptics (VA and DIVA series), antidepressants (Duloxetine), and treatments for Alzheimer’s disease. SCI distinguishes itself through a vertically integrated model that includes custom manufacturing (CMO/CDMO) for international clients, particularly in the U.S. and Europe, leveraging its long-standing regulatory approvals from the FDA, PMDA, and EDQM. Its primary competitors include ScinoPharm Taiwan (1789), Formosa Laboratories (4746), and Chung Hwa Chemical Industrial (1762); SCI maintains a competitive edge by dominating niche markets for small-molecule APIs and maintaining a robust global export footprint. The company was originally established in 1987 as a joint venture with Switzerland’s Siegfried Ltd. before being acquired in 2001 by the Mercuries Group (三商集團), which remains the dominant institutional investor through Mercuries & Associates Holding, Ltd. (holding approximately 30% of shares). The current leadership is led by Chairman Dr. Wei-Chyun Wong, a PhD in Chemistry from the University of Pennsylvania with extensive research experience at the Industrial Technology Research Institute (ITRI), and General Manager Dr. Wen-Chih Chou, who holds a PhD from National Taiwan University and previously served as the company’s R&D manager. The board is further strengthened by representatives from the Mercuries Group and independent directors with backgrounds in international law and finance, ensuring a robust governance structure that supports SCI’s ongoing expansion into high-growth therapeutic areas and its continued recovery following its 2020 facility reconstruction.